Mutational heterogeneity in cancer and the search for new cancer-associated genes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reproducibility of scientific findings has been called into question.”
From Evaluating replicability of laboratory experiments in economics (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Melanoma has one of the highest rates of mutation of any cancer16.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells are genetically unstable, which contributes to their uncontrolled proliferation and the expression of antigens that can be recognized by the immune system.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…(GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8 ; MUC4 in melanoma 13 ; olfactory receptor OR2L13 in GBM 14 ; and TTN in breast cancer 12 and other tumor types 15 .”
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“…genes have already cropped up in recently published cancer genome studies, for example: LRP1B in glioblastoma (GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8…”
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504 · cited 2×
“Recent studies have also implicated HPV in head-and-neck cancers 5 .”
InfluentialSelf-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · cited 3×
“Recent work 19,20 has shown that the TpC mutations tend to occur in proximity to one another, consistent with the activity of APOBEC enzymes in damaged long single-strand DNA regions.”
Influential
Cited by
Items 601–700 of 1,039
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C.-H., Yelensky, R., Jooss, K., & Chan, T. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 162
Applications and analysis of targeted genomic sequencing in cancer studies
Bewicke‐Copley, F., Kumar, E. A., Palladino, G., Korfi, K., & Wang, J. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.10.004 · Cited by 184
Wang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 163
Aguiar, P. N., Santoro, I. L., Tadokoro, H., de Lima Lopes, G., Filardi, B. A., Oliveira, P., Mountzios, G., & de Mello, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2015-0002 · Cited by 160
Tug-of-war between driver and passenger mutations in cancer and other adaptive processes
McFarland, C. D., Mirny, L. A., & Korolev, K. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404341111 · Cited by 156
Danilova, L., Wang, H., Sunshine, J., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 161
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Chatila, W. K., Kim, J. K., Walch, H., Marco, M. R., Chen, C.-T., Wu, F., Omer, D. M., Khalil, D. N., Ganesh, K., Qu, X., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01930-z · Cited by 156
Self-citationBabur, Ö., Gönen, M., Aksoy, B. A., Schultz, N., Ciriello, G., Sander, C., & Demir, E. (2015) · Genome Biology · doi:10.1186/s13059-015-0612-6 · Cited by 166
MUFFINN: cancer gene discovery via network analysis of somatic mutation data
Cho, A., Shim, J. E., Kim, E., Supek, F., Lehner, B., & Lee, I. (2016) · Genome Biology · doi:10.1186/s13059-016-0989-x · Cited by 160
Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Zhao, X., & Subramanian, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2379 · Cited by 157
Eischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161
Evolutionary history of human colitis-associated colorectal cancer
Baker, A.-M., Cross, W., Curtius, K., Al Bakir, I., Choi, C.-H. R., Davis, H. L., Temko, D., Biswas, S., Martinez, P., Williams, M. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316191 · Cited by 161
Jespersen, H., Lindberg, M. F., Donia, M., Söderberg, E. M. V., Andersen, R., Keller, U., Ny, L., Svane, I. M., Nilsson, L. M., & Nilsson, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00786-z · Cited by 160
Reduced mutation rate in exons due to differential mismatch repair
Frigola, J., Sabarinathan, R., Mularoni, L., Muiños, F., Gonzalez-Perez, A., & López-Bigas, N. (2017) · Nature Genetics · doi:10.1038/ng.3991 · Cited by 155
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123626 · Cited by 153
Clinical impact of tumour biology in the management of gastroesophageal cancer
Lordick, F., & Janjigian, Y. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.15 · Cited by 161
Wienand, K., Chapuy, B., Stewart, C., Dunford, A. J., Wu, D., Kim, J., Kamburov, A., Wood, T. R., Cader, F. Z., Ducar, M. D., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019001012 · Cited by 159
Self-citationPreclinical murine tumor models: A structural and functional perspective
Guérin, M. V., Finisguerra, V., den Eynde, B. J. V., Bercovici, N., & Trautmann, A. (2020) · eLife · doi:10.7554/elife.50740 · Cited by 167
Aynaud, M.-M., Mirabeau, O., Gruel, N., Grossetête, S., Boeva, V., Durand, S., Surdez, D., Saulnier, O., Zaïdi, S., Gribkova, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.049 · Cited by 171
Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth
Kim, K. H., & Roberts, C. W. M. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.04.004 · Cited by 158
Self-citationJiang, Y., Wang, J., Sun, M., Zuo, D., Wang, H., Shen, J., Jiang, W., Mu, H., Ma, X., Yin, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34689-5 · Cited by 142
Kehrer‐Sawatzki, H., Farschtschi, S. C., Mautner, V., & Cooper, D. N. (2016) · Human Genetics · doi:10.1007/s00439-016-1753-8 · Cited by 169
Akalu, Y. T., Rothlin, C. V., & Ghosh, S. (2017) · Immunological Reviews · doi:10.1111/imr.12522 · Cited by 153
Khunger, M., Hernandez, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J., Mukhopadhyay, S., Schalper, K., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 154
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
Gros, A., Tran, E., Parkhurst, M. R., Ilyas, S., Pasetto, A., Groh, E. M., Robbins, P. F., Yossef, R., Garcia-Garijo, A., Fajardo, C. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127967 · Cited by 155
Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition
Lujan, S. A., Clausen, A. R., Clark, A. B., MacAlpine, H. K., MacAlpine, D. M., Malc, E. P., Mieczkowski, P. A., Burkholder, A. B., Fargo, D. C., Gordenin, D. A., et al. (2014) · Genome Research · doi:10.1101/gr.178335.114 · Cited by 152
Self-citationGenomic landscape of adenoid cystic carcinoma of the breast
Martelotto, L. G., Filippo, M. R. D., Ng, C. K. Y., Natrajan, R., Fuhrmann, L., Cyrta, J., Piscuoglio, S., Wen, H., Lim, R. S., Shen, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4573 · Cited by 167
Interactome INSIDER: a structural interactome browser for genomic studies
Meyer, M. J., Beltrán, J. F., Liang, S., Fragoza, R., Rumack, A., Liang, J., Wei, X., & Yu, H. (2018) · Nature Methods · doi:10.1038/nmeth.4540 · Cited by 159
Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 154
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036
Garbe, C., Keim, U., Gandini, S., Amaral, T., Katalinic, A., Hollezcek, B., Martus, P., Flatz, L., Leiter, U., & Whiteman, D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.029 · Cited by 146
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
“Moreover, tumor heterogeneity is an important determinant in the development of drug resistance (Alizadeh et al., 2015; Andor et al., 2016; Lawrence et al., 2013; Swanton, 2012): both genetic and nongenetic mechanisms contribute to the generation of different subpopulations of cancer cells within…”
BackgroundGenetic Variation in Human DNA Replication Timing
Koren, A., Handsaker, R. E., Kamitaki, N., Karlić, R., Ghosh, S., Polak, P., Eggan, K., & McCarroll, S. A. (2014) · Cell · doi:10.1016/j.cell.2014.10.025 · Cited by 157
“…phases of replication are faster, less structured (Koren and McCarroll, 2014), and more mutation-prone; late-replicating loci have elevated mutation rates in the human germline (Stamatoyannopoulos et al., 2009), in somatic cells (Koren et al., 2012), and in cancer cells (Lawrence et al., 2013).”
Self-citationCho, S. Y., Park, J. W., Liu, Y., Park, Y. S., Kim, J. H., Yang, H. P., Um, H., Ko, W. R., Lee, B. I., Kwon, S. Y., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.012 · Cited by 175
Self-citationCRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
Chen, L., Alexe, G., Dharia, N. V., Ross, L., Iniguez, A. B., Conway, A. S., Wang, E. J., Veschi, V., Lam, N., Qi, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90793 · Cited by 152
Self-citationThe reverse evolution from multicellularity to unicellularity during carcinogenesis
Chen, H., Lin, F., Xing, K., & He, X. (2015) · Nature Communications · doi:10.1038/ncomms7367 · Cited by 176
Early and multiple origins of metastatic lineages within primary tumors
Zhao, Z.-M., Zhao, B., Bai, Y., Iamarino, A., Gaffney, S. G., Schlessinger, J., Lifton, R. P., Rimm, D. L., & Townsend, J. P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525677113 · Cited by 158
Starrett, G. J., Luengas, E. M., McCann, J. L., Ebrahimi, D., Temiz, N. A., Love, R. P., Feng, Y., Adolph, M. B., Chelico, L., Law, E. K., et al. (2016) · Nature Communications · doi:10.1038/ncomms12918 · Cited by 169
Andrysik, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M., Inga, A., & Espinosa, J. M. (2017) · Genome Research · doi:10.1101/gr.220533.117 · Cited by 154
“ground, accounting also for factors such as gene length, chromatin state, and transcription rate, using MutSigCV (Lawrence et al. 2013).”
InfluentialThe Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 149
“In cancer and other complex diseases, the power to detect important germline variants or somatic mutations has been hampered by the extreme genetic heterogeneity observed across the patient population (Gerlinger et al., 2012; Lawrence et al., 2013; Longo, 2012; Zhang et al., 2014).”
BackgroundInfluentialOncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Martin, N. T., & Bell, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.001 · Cited by 160
Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features
Bergquist, J. R., Leiting, J. L., Habermann, E. B., Cleary, S. P., Kendrick, M. L., Smoot, R. L., Nagorney, D. M., Truty, M. J., & Grotz, T. E. (2019) · Surgery · doi:10.1016/j.surg.2019.04.036 · Cited by 163
Zygotic genome activation by the totipotency pioneer factor Nr5a2
Gassler, J., Kobayashi, W., Gáspár, I., Ruangroengkulrith, S., Mohanan, A., Hernández, L. G., Kravchenko, P., Kümmecke, M., Lalic, A., Rifel, N., et al. (2022) · Science · doi:10.1126/science.abn7478 · Cited by 168
Mutational landscape of cancer-driver genes across human cancers
Sinkala, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-39608-2 · Cited by 176
“…CSMD1, CSMD3, NRXN1, NRXN4, CNTNAP2, CNTNAP4, CNTNAP5, CNTN5, PARK2, LRP1B, PCLO, MUC16, MUC4, KMT2C, KMT2A, KMT2D, FAT1, FAT2, FAT3, and FAT4 ) were not identified as being significantly mutated using MutSigCV2 in a specific cancer type, it was excluded from the analysis for that cancer type 84 .”
A first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Self-citationEngineering anti‐GD2 monoclonal antibodies for cancer immunotherapy
Ahmed, M., & Cheung, N. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.030 · Cited by 159
Waanders, E., Gu, Z., Dobson, S. M., Antić, Ž., Crawford, J. C., Ma, X., Edmonson, M. N., Payne-Turner, D., van de Vorst, M., Jongmans, M. C. J., et al. (2020) · Blood Cancer Discovery · doi:10.1158/0008-5472.bcd-19-0041 · Cited by 163
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation
Gingras, M., Covington, K. R., Chang, D. K.-F., Donehower, L. A., Gill, A. J., Ittmann, M., Creighton, C. J., Johns, A. L., Shinbrot, E., Dewal, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.005 · Cited by 156
Qin, H.-D., Liao, X., Chen, Y., Huang, S.-Y., Xue, W., Li, F.-F., Ge, X.-S., Liu, D.-Q., Cai, Q., Long, J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.02.021 · Cited by 159
The Genomic Landscape of Male Breast Cancers
Piscuoglio, S., Ng, C. K. Y., Murray, M. P., Guerini‐Rocco, E., Martelotto, L. G., Geyer, F. C., Bidard, F., Berman, S., Fusco, N., Sakr, R. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2840 · Cited by 172
Lugowska, I. A., Teterycz, P., & Rutkowski, P. L. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73889 · Cited by 171
Cheng, F., Zhao, J., & Zhao, Z. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv068 · Cited by 161
Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer
Nordentoft, I., Lamy, P., Birkenkamp‐Demtröder, K., Shumansky, K., Vang, S., Hornshøj, H., Juul, M., Villesen, P., Hedegaard, J., Roth, A. J. L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.038 · Cited by 163
Accumulation of Somatic Mutations in TP53 in Gastric Epithelium With Helicobacter pylori Infection
Shimizu, T., Marusawa, H., Matsumoto, Y. M., Inuzuka, T., Ikeda, A., Fujii, Y., Minamiguchi, S., Miyamoto, S., Kou, T., Sakai, Y., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.036 · Cited by 161
Cancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
Guo, C. C., Majewski, T., Zhang, L., Yao, H., Bondaruk, J. E., Wang, Y., Zhang, S., Wang, Z., Lee, J. G., Lee, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.048 · Cited by 163
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Arang, N., & Gutkind, J. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.14017 · Cited by 157
Wu, X., Zhang, H., Chen, J., Shang, S., Wei, Q., Yan, J., & Tu, X. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7257-y · Cited by 161
Kuperstein, I., Bonnet, E., Nguyen, H.-A., Cohen, D., Viara, E., Grieco, L., Fourquet, S., Calzone, L., Russo, C., Kondratova, M., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.19 · Cited by 143
Deep whole-genome analysis of 494 hepatocellular carcinomas
Chen, L., Zhang, C., Xue, R., Liu, M., Bai, J., Bao, J., Wang, Y., Jiang, N., Li, Z., Wang, W., et al. (2024) · Nature · doi:10.1038/s41586-024-07054-3 · Cited by 148
Interpreting the Dependence of Mutation Rates on Age and Time
Gao, Z., Wyman, M. J., Sella, G., & Przeworski, M. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002355 · Cited by 145
Nairismägi, M., Tan, J. Y., Lim, J. Q., Nagarajan, S., Ng, C. C. Y., Rajasegaran, V., Huang, D., Lim, W. K., Laurensia, Y., Wijaya, G.-C., et al. (2016) · Leukemia · doi:10.1038/leu.2016.13 · Cited by 158
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma
Arthur, S. E., Jiang, A., Grande, B. M., Alcaide, M., Cojocaru, R., Rushton, C. K., Mottok, A., Hilton, L. K., Lat, P. K., Zhao, E. Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06354-3 · Cited by 146
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., Li, S., Zhang, J., Ying, X., Cheng, X., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1356144 · Cited by 145
Cancer driver mutations: predictions and reality
Ostroverkhova, D. S., Przytycka, T. M., & Panchenko, A. R. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.03.007 · Cited by 161
Rendeiro, A. F., Schmidl, C., Strefford, J. C., Walewska, R., Davis, Z., Farlik, M., Oscier, D., & Bock, C. (2016) · Nature Communications · doi:10.1038/ncomms11938 · Cited by 146
Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis
Georgakopoulos-Soares, I., Morganella, S., Jain, N., Hemberg, M., & Nik-Zainal, S. (2018) · Genome Research · doi:10.1101/gr.231688.117 · Cited by 146
Landscape of Genomic Alterations in Pituitary Adenomas
Bi, W. L., Horowitz, P. M., Greenwald, N. F., Abedalthagafi, M., Agarwalla, P. K., Gibson, W. J., Mei, Y., Schumacher, S. E., Ben‐David, U., Chevalier, A. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0790 · Cited by 147
“may be mechanistically favored rather than selected (42).”
Self-citationMethods for copy number aberration detection from single-cell DNA-sequencing data
Mallory, X., Edrisi, M., Navin, N. E., & Nakhleh, L. K. (2020) · Genome biology · doi:10.1186/s13059-020-02119-8 · Cited by 162
Miller, A., Asmann, Y., Cattaneo, L., Braggio, E., Keats, J., Auclair, D., Lonial, S., The MMRF CoMMpass Network, Russell, S. J., & Stewart, A. K. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.94 · Cited by 145
Self-citationChun, H.-J. E., Lim, E. L., Heravi‐Moussavi, A., Saberi, S., Mungall, K., Bilenky, M., Carles, A., Tse, K., Shlafman, I., Zhu, K., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.009 · Cited by 157
“As expected (Lawrence et al., 2013; Lee et al., 2012), somatic SNV rates in MRTs were low (median of 612.5 per case, 0.231 mutations/Mb; Figure 1) with 97.1% of mutations in non-coding regions.”
InfluentialSustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
Nagarajah, J., Le, M., Knauf, J. A., Ferrandino, G., Montero-Conde, C., Pillarsetty, N., Bolaender, A., Irwin, C., Krishnamoorthy, G. P., Saqcena, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci89067 · Cited by 141
Zhai, W., Lim, T. K.-H., Zhang, T., Phang, S.-T., Tiang, Z., Guan, P., Ng, M.-H., Lim, J. Q., Yao, F., Li, Z., et al. (2017) · Nature Communications · doi:10.1038/ncomms14565 · Cited by 147
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
Rolfo, C. D., Caglevic, C., Santarpía, M., Araújo, A., Giovannetti, E., Gallardo, C. D., Pauwels, P., & Mahave, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_5 · Cited by 153
Hosen, N., Matsunaga, Y., Hasegawa, K., Matsuno, H., Nakamura, Y., Makita, M., Watanabe, K., Yoshida, M., Satoh, K., Morimoto, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4431 · Cited by 150
Evolutionary trajectories of small cell lung cancer under therapy
George, J., Maas, L., Abedpour, N., Cartolano, M., Kaiser, L., Fischer, R. N., Scheel, A. H., Weber, J.-P., Hellmich, M., Bosco, G., et al. (2024) · Nature · doi:10.1038/s41586-024-07177-7 · Cited by 158
“To complement our analytical approach we also used other computational tools to study significant gene alterations, including MutSig2CV 51 , dNdSCV 52 and OncodriveFML 53 .”
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines
Martin, S. D., Brown, S. D., Wick, D. A., Nielsen, J. S., Kroeger, D. R., Twumasi-Boateng, K., Holt, R. A., & Nelson, B. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155189 · Cited by 137
The landscape of driver mutations in cutaneous squamous cell carcinoma
Chang, D., & Shain, A. H. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00226-4 · Cited by 157
A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population
Qu, Y., Feng, J., Wu, X., Bai, L., Xu, W., Zhu, L., Liu, Y., Xu, F., Zhang, X., Yang, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29577-x · Cited by 167
Nguyen, E. M., Taniguchi, H., Chan, J. M., Zhan, Y. A., Chen, X., Qiu, J. J., de Stanchina, E., Allaj, V., Shah, N., Uddin, F. Z., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.014 · Cited by 158
Robey, R. B., Weisz, J., Kuemmerle, N. B., Salzberg, A. C., Berg, A. S., Brown, D. G., Maurer, L. L., Palorini, R., Al‐Mulla, F., Al-Temaimi, R. A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv037 · Cited by 164
Somatic mutations, genome mosaicism, cancer and aging
Vijg, J. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.04.002 · Cited by 138
Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer
Carter, H., Marty, R., Hofree, M., Gross, A. M., Jensen, J., Fisch, K. M., Wu, X., DeBoever, C., Van Nostrand, E. L., Song, Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1045 · Cited by 146
Forget, M., Haymaker, C., Hess, K. R., Meng, Y. J., Creasy, C. A., Karpinets, T. V., Fulbright, O. J., Roszik, J., Woodman, S. E., Kim, Y. U., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3649 · Cited by 145
Glaser, A. P., Fantini, D., Wang, Y., Yu, Y., Rimar, K. J., Podojil, J. R., Miller, S. D., & Meeks, J. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23344 · Cited by 159
Wang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1448 · Cited by 148
Viruses and the DNA Damage Response: Activation and Antagonism
Luftig, M. A. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085548 · Cited by 158
Protein-structure-guided discovery of functional mutations across 19 cancer types
Niu, B., Scott, A. D., Sengupta, S., Bailey, M. H., Batra, P., Ning, J., Wyczalkowski, M. A., Liang, W.-W., Zhang, Q., McLellan, M. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3586 · Cited by 142
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications
Pasquali, S., & Gronchi, A. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017705588 · Cited by 143
Klega, K., Imamovic-Tuco, A., Ha, G., Clapp, A. N., Meyer, S., Ward, A., Clinton, C., Nag, A., Van Allen, E., Mullen, E., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00285 · Cited by 136
Self-citationHierarchical HotNet: identifying hierarchies of altered subnetworks
Reyna, M. A., Leiserson, M. D. M., & Raphael, B. J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty613 · Cited by 138
Extremely rare variants reveal patterns of germline mutation rate heterogeneity in humans
Carlson, J., Locke, A. E., Flickinger, M., Zawistowski, M., Levy, S., Myers, R. M., Boehnke, M., Kang, H. M., Scott, L. J., Li, J. Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05936-5 · Cited by 130
Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152
NF 1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
Cirenajwis, H., Lauss, M., Ekedahl, H., Törngren, T., Kvist, A., Saal, L. H., Olsson, H. L., Staaf, J., Carneiro, A., Ingvar, C., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12050 · Cited by 156
Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
Malaker, S. A., Penny, S. A., Steadman, L. G., Myers, P. T., Loke, J. C., Raghavan, M., Bai, D. L., Shabanowitz, J., Hunt, D. F., & Cobbold, M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0280 · Cited by 140
“3 immunity could be responsible for the dramatic reductions in tumor volume seen (7, 12).”
Rogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
Heppt, M. V., Amaral, T. M. S., Kähler, K. C., Heinzerling, L., Hassel, J. C., Meißner, M., Kreuzberg, N., Loquai, C., Reinhardt, L., Utikal, J. S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0800-0 · Cited by 141
DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies
Han, Y., Yang, J., Qian, X., Cheng, W.-C., Liu, S.-H., Hua, X., Zhou, L., Yang, Y., Wu, Q., Liu, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz096 · Cited by 136
“It is widely used for TCGA projects (9).”
BackgroundInfluentialStrohl, W. R., & Naso, M. (2019) · Antibodies · doi:10.3390/antib8030041 · Cited by 134
“Several genomic studies have revealed the extreme heterogeneity within tumors and even a wide range of heterogeneity amongst patients with a single type of tumor and heterogeneity amongst different types of tumors [377,378].”
Inhibition of p53 inhibitors: progress, challenges and perspectives
Sanz, G., Singh, M., Peuget, S., & Selivanova, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz075 · Cited by 138
Pearson, A., Proszek, P., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4044 · Cited by 136
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D.-A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- National Institutes of Health (US)
- Harvard University (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Lawrence, Michael S.
- Polak, Paz
- Kryukov, Gregory V.
- Cibulskis, Kristian
- Sivachenko, Andrey
- Carter, Scott L.
- Stewart, Chip
- Mermel, Craig H.
- Roberts, Steven A.
- Hammerman, Peter S.
- McKenna, Aaron
- Drier, Yotam
- Zou, Lihua
- Pugh, Trevor J.
- Stransky, Nicolas
- Helman, Elena
- Kim, Jaegil
- Auclair, Daniel
- Saksena, Gordon
- Noble, Michael
- Lin, Pei
- Heiman, David I.
- Imielinski, Marcin
- Hernandez, Bryan
- Hodis, Eran
- Baca, Sylvan
- Dulak, Austin M.
- Lohr, Jens
- Landau, Dan-Avi
- Wu, Catherine J.
- Koren, Amnon
- McCarroll, Steven A.
- Mora, Jaume
- Crompton, Brian
- Winckler, Wendy
- Ardlie, Kristin
- Gabriel, Stacey B.
- Roberts, Charles W. M.
- Biegel, Jaclyn A.
- Stegmaier, Kimberly
- Bass, Adam J.
- Garraway, Levi A.
- Meyerson, Matthew
- Golub, Todd R.
- Gordenin, Dmitry A.
- Sunyaev, Shamil
- Lander, Eric S.
- Getz, Gad
- Venue
- Nature
- Published
- 2013-06-16
- Volume
- 499
- Issue
- 7457
- Pages
- 214-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3919509
- OpenAlex
- W2009720434
- Cited by
- 5,461
- References
- 30
- Citations by year
- 2026: 147 · 2025: 230 · 2024: 288 · 2023: 361 · 2022: 468 · 2021: 580 · 2020: 582 · 2019: 507 · 2018: 537 · 2017: 529 · 2016: 485 · 2015: 396 · 2014: 280 · 2013: 64
- FWCI
- 143.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U24CA143845, T32CA009216, T32CA009172)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Environmental Health Sciences (Z01ES065073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- mutational heterogeneity, cancer genes, MutSigCV, driver mutations, mutation frequency, lung cancer, lung squamous cell carcinoma, DNA replication timing, transcriptional activity
- MeSH terms
- False Positive Reactions, Humans, Lung Neoplasms, Mutation, Neoplasms, Oncogenes, Reproducibility of Results, Gene Expression, Genome, Human, Artifacts, Neoplasms, Squamous Cell, Sample Size, Genetic Heterogeneity, DNA Replication Timing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.